Ontario individuals who are immunocompromised can get a fourth dose

by admin | Apr 19, 2024 | Article

Ontario individuals who are immunocompromised can get a fourth dose (booster) three months (84 days) after completion of the three-dose primary series. Please visit https://covid-19.ontario.ca/getting-covid-19-vaccine for more information.

Government of Canada signs new COVID-19 antibody therapy agreement

by admin | Apr 19, 2024 | Article

Please visit https://www.canada.ca/en/public-services-procurement/news/2022/02/government-of-canada-signs-new-covid-19-antibody-therapy-agreement.html for details.

Canadian Rheumatology Association Position Statement on COVID-19 Vaccination

by admin | Apr 19, 2024 | Article

Please visit https://rheum.ca/wp-content/uploads/2022/03/FINAL-Updated-PS-on-COVID-19-Vacc-March-25_2022_for-publication.pdf for details.

Lupus Canada is pleased to share that Health Canada has approved Evusheld for pre-exposure prophylaxis of COVID-19 in immune-compromised individuals.

by admin | Apr 19, 2024 | Article

Evusheld is now approved for use in adults and children (12 years of age and older, weighing at least 40 kg) who are not currently infected with COVID-19 and have not had recent known contact with someone infected with COVID-19, and: who are immune...

GSK’s Belimumab shows significant improvement in renal function in the largest Lupus Nephritis (LN) clinical study

by admin | Apr 19, 2024 | Article

In the most extensive study to date, GSK’s Belimumab (alongside Standard therapy) vs. placebo showed a significant improvement in LN renal response, such as renal filtration and urine protein creatinine. Moreover, Belimumab also demonstrated a favorable safety...